Syneos Health ((SYNH)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent clinical study update, Syneos Health, in collaboration with GATT Technologies BV, has completed a pivotal investigation titled A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of GATT-Patch Versus TachoSil for Hemostasis During Open Liver Surgery. The study aimed to assess the safety and performance of the GATT-Patch, now named ETHIZIA, compared to TachoSil in managing bleeding during elective open liver surgeries. This study is significant as it seeks to provide a new solution for controlling surgical bleeding, potentially improving patient outcomes.
The interventions tested in this study include the GATT-Patch (ETHIZIA), an experimental hemostatic patch designed to aid in surgical bleeding control, and TachoSil, an active comparator known for its fibrin sealant properties. Both are intended to assist in managing bleeding when traditional methods are insufficient.
The study followed an interventional design with randomized allocation and a parallel intervention model. Participants were blinded to the treatment they received, ensuring unbiased results. The primary purpose was to evaluate treatment efficacy.
The study began on August 4, 2022, and was completed with the last update submitted on August 18, 2025. These dates are crucial as they mark the timeline of the study’s progression and its recent completion, providing a basis for future developments and potential market entry.
This update could influence Syneos Health’s stock performance positively, as successful study outcomes might enhance investor confidence and market positioning. With competitors in the hemostatic patch market, such advancements could shift industry dynamics, potentially benefiting Syneos Health and its collaborators.
The study is now completed, with further details available on the ClinicalTrials portal.